PSA screening shenanigans??


There was an editorial in the NY Times 11/26/14 written by the pathologist who discovered PSA in 1970 (and writer of a book on it, called "the great prostate hoax: how big medicine hijacked the psa test and caused a public health disaster" -- see http://www.nytimes.com/2014/11/26/opinion/the-problem-with-prostate-screening.html?ref=opinion&_r=0​ .  there was also a recent interview of him by Eric Topol -- see http://www.medscape.com/viewarticle/828854_1​ . his basic comments:

--in reviewing the European Randomized Study of Screening for Prostate Cancer (ERSPC), and the Swedish Goteberg study (which was the basis for the European one) and had a 44% reduction in prostate cancer deaths, they refused to allow outside investigators to review the data. (the 11-year followup reported in NEJM from the whole  ERSPC was 29% reduction in those adherent to the study-- see N Engl J Med 2012; 366:981-990)
--there were inherent concerns about about the methadology, including transferring 60% of the data from Goteberg to the ERSPC, strongly tipping the balance of the 7-country study by this one country which showed such a dramatic positive result.
--there were significant conflicts of interest in the investigators, being involved in companies that market PSA tests or related technologies.

so, just muddies the water a bit more (and who would have thought they could be muddier). the US study, also reported in NEJM (see N Engl J Med 2009; 360:1310-1319), did not find benefit from screening, though had its own issues (much contamination of the groups). Ablin might also have his own issues: he discovered the PSA test, targeted it for use as a marker to follow known prostate cancer and not a screening test, may be promoting his book, etc. but it is certainly concerning if the most positive study (ERSPC) is potentially biased by a single Swedish study, and they will not release their data for review.....

Comments

Post a Comment

if you would like to receive the near-daily emails regularly, please email me at gmodest@uphams.org

Popular posts from this blog

HDL a negative risk factor? or cholesterol efflux??

Although the data on HDL being protective of atherosclerotic disease is pretty consistent, there are negative studies, and the data on medications which dramatically improve HDL levels (eg, the cholesteryl ester transfer protein --CETP --inhibitors, such as torcetrapib) are clinically disappointing. there have been several explanations for this. for example, some HDL particles are "pro-inflammatory" and elicit an atherosclerotic response (which may be related to apolipoprotein C-III). a new article in NEJM highlights another angle -- that the issue is not the HDL number, but HDL's functionality in the reverse transport of cholesterol, as measured by the cholesterol efflux capacity (see  lipids HDL efflux capacity vs amt NEJM 2014 in dropbox, or  DOI: 10.1056/NEJMoa1409065). This article looks at the Dallas Heart Study, where they measured HDL levels, HDL particle concentrations, and cholesterol efflux capacity in 2924 adults free of cardiovascular disease and followed p
Read more

Drug company shenanigans: narcolepsy drug

I have not done a blog for a long time on drug company shenanigans. So it is my great pleasure to bring up a brand-new drug company approach to garner huge amounts of money (see  https://www.nytimes.com/2023/02/28/business/jazz-narcolepsy-avadel-patents.html?smid=nytcore-ios-share&referringSource=articleShare  ).  Based on an article by  Rebecca Robbins of the New York Times, who has written several articles on drug company excesses   As background, this will be my 42 nd  such blog: for the array, see  https://bucommunitymed.wpengine.com/page/4/?s=drug+company+shenanigans   Th e drug company  approach  this time  to extending  their  patents has a few “interesting” angles: -- this is a medication manufactured by Jazz Pharmaceuticals to treat narcolepsy: there are 2 versions: Xyrem and Xywav (Xywav has less sodium, so is marketed to those who should be on a low sodium diet). These meds are basically derivatives of gammahydroxybutyric acid (GHB)      -- the drug actually has a pretty
Read more

UPDATE: ASCVD risk factor critique

  I decided to do an extensive update of my prior ASCVD (atherosclerotic cardiovascular disease) risk analysis and critique of risk calculators, with much more information about the “non-traditional” risk factors. I felt that there should be more data/clarification, since I think we are really undertreating/not preventing the most common cause of death by relying on the ASCVD risk calculators   -- Cardiovascular risk models:      -- many of us rely on the various cardiovascular risk models to determine the appropriate approach to patients, and these are often integrated into the electronic medical records      -- these risk models have several very important limitations:          -- they are typically based on community data, eg from the Framingham study etc. But, in clinical practice, we are dealing with the individual and not the community:              -- there is very clear evidence that there are many individual risk factors that are associated with increased risk of a cardiovascu
Read more